Axcella OKd to Register for Long COVID Fatigue Treatment

 Phase 2b/3 study may proceed under U.S. Investigational New Drug application

Study design now accepted by U.S. and U.K. regulatory authorities

Axcella to present at Long COVID forum co-sponsored by BIO and Solve M.E.

Axcella to host a conference call February 16 at 8:00 a.m. ET; To register, click here

https://finance.yahoo.com/news/axcella-announces-fda-ind-clearance-211000038.html